Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma by Konstantinopoulos, Panagiotis A. et al.
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination
With Pembrolizumab in PatientsWith Recurrent
Platinum-Resistant Ovarian Carcinoma
Panagiotis A. Konstantinopoulos, MD, PhD; StevenWaggoner, MD; Gregory A. Vidal, MD; Monica Mita, MD; JohnW. Moroney, MD; Robert Holloway, MD;
Linda Van Le, MD; Jasgit C. Sachdev, MD; Eloise Chapman-Davis, MD; Gerardo Colon-Otero, MD; Richard T. Penson, MD; Ursula A. Matulonis, MD;
Young Bae Kim, MD; Kathleen N. Moore, MD; ElizabethM. Swisher, MD; Anniina Färkkilä, MD; Alan D’Andrea, MD; Erica Stringer-Reasor, MD;
JingWang, PhD; Nathan Buerstatte, MPH; Sujata Arora, MS; Julie R. Graham, PhD; Dmitri Bobilev, MD; Bruce J. Dezube, MD; Pamela Munster, MD
IMPORTANCE Patients with recurrent ovarian carcinoma frequently develop resistance to
platinum-based chemotherapy, at which time treatment options become limited.
OBJECTIVE To evaluate the poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitor
niraparib combined with pembrolizumab in patients with recurrent ovarian carcinoma.
DESIGN, SETTING, AND PARTICIPANTS The TOPACIO/KEYNOTE-162 (Niraparib in Combination
With Pembrolizumab in Patients With Triple-Negative Breast Cancer or Ovarian Cancer) trial,
an open-label, single-arm phases 1 and 2 study enrolled womenwith advanced or metastatic
triple-negative breast cancer (TNBC) or recurrent ovarian carcinoma, irrespective of BRCA
mutation status. Median follow-up was 12.4 months (range, 1.2 to23.0months). Data were
collected from April 15, 2016, through September 4, 2018, with September 4, 2018, as a data
cutoff, and analyzed from September 4, 2018, through January 30, 2019.
INTERVENTIONS The recommended phase 2 dose (RP2D) was 200mg of oral niraparib once
daily and 200mg of intravenous pembrolizumab on day 1 of each 21-day cycle.
MAIN OUTCOMES ANDMEASURES The primary objectives of phase 1 were to evaluate
dose-limiting toxic effects and establish the RP2D and dosing schedule. The primary objective
of phase 2 was to assess objective response rate (ORR; complete plus partial responses).
Results from the phase 1 ovarian carcinoma and TNBC cohorts and phase 2 ovarian carcinoma
cohort are reported. Because of the similarity in the phase 1 and 2 ovarian carcinoma
populations, the data were pooled to perform an integrated efficacy analysis.
RESULTS Fourteen patients (9 with ovarian carcinoma and 5 with TNBC) in phase 1 and 53
patients with ovarian carcinoma in phase 2 were enrolled, for a pooled ovarian carcinoma
cohort of 62 patients (median age, 60 years [range, 46-83 years]). In the integrated efficacy
phases 1 and 2 ovarian carcinoma population (60 of 62 evaluable patients), ORRwas 18%
(90%CI, 11%-29%), with a disease control rate of 65% (90%CI, 54%-75%), including 3 (5%)
with confirmed complete responses, 8 (13%) with confirmed partial responses, 28 (47%)
with stable disease, and 20 (33%) with progressive disease. The ORRs were consistent across
subgroups based on platinum-based chemotherapy sensitivity, previous bevacizumab
treatment, or tumor BRCA or homologous recombination deficiency (HRD) biomarker status.
Median duration of response was not reached (range, 4.2 to14.5 months). At data cutoff,
2 patients with a response and 1 patient with stable disease continued to receive treatment.
CONCLUSIONS AND RELEVANCE Niraparib in combination with pembrolizumab is tolerable,
with promising antitumor activity for patients with ovarian carcinomawho have limited
treatment options regardless of platinum status, biomarker status, or prior treatment with
bevacizumab. Responses in patients without tumor BRCAmutations or non-HRD cancers
were higher than expected with either agent as monotherapy.
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O varian cancer is the eighth leading cause of deathsdue to cancer worldwide, with a 5-year survival rateranging from30%to50%.Althoughmostpatients ini-
tially have platinum-sensitive ovarian carcinoma, their dis-
ease eventually becomes resistant or refractory to platinum-
based chemotherapy.1,2 Some patients are unable to receive
platinum-based chemotherapy owing to cumulative toxic ef-
fects or allergic reactions and receive non–platinum-based
agents such as weekly paclitaxel, pegylated liposomal doxo-
rubicinhydrochloride, or topotecanhydrochloride aloneor in
combination with bevacizumab.3,4 Owing to the risk of vas-
cular toxic effects andgastrointestinal tract perforation, beva-
cizumab is contraindicated in approximately one-third of
patients5; non–platinum-based monotherapy in these pa-
tients results in low response rates (10%-15%) and short du-
rations of response (3-4 months).6
The treatment armamentarium for ovarian carcinoma
has recently been expanded to include poly(adenosine
diphosphate–ribose) polymerase (PARP) inhibitors. PARPs
are enzymes that detect DNA damage and promote repair by
several mechanisms. Inhibition of PARP1/2 in cells that
are already deficient in DNA repair mechanisms, such as
those with BRCA (OMIM 113705 and 600185) mutations or
homologous recombination deficiency (HRD), causes
increased genomic instability and ultimately cell death. This
synergism between cellular defect and drug-induced effect
is termed synthetic lethality. Patients with BRCA wild-type
(BRCAwt) tumors also benefit from PARP inhibition induced
by niraparib; this effect is thought to be driven by high
tumor accumulation of niraparib.7 Niraparib is approved
in the United States and European Union for the mainte-
nance treatment of recurrent ovarian carcinoma for patients
with a complete or partial response to platinum-based
chemotherapy.8,9 This approval was based on results from
the European Network of Gynaecological Oncological
Trial Groups (ENGOT)-OV16/NOVA trial,10 which demon-
strated that treatment with niraparib significantly improved
progression-free survival along a graduated continuum.
The strongest effect was observed in patients with germline
BRCA-mutated (gBRCAmut) tumors (hazard ratio [HR],
0.27), followed by patients with HRD-positive/gBRCAwt
tumors (HR, 0.38) and those with HRD-negative tumors (HR,
0.58).10
Programmedcell death receptor 1 (PD-1) is a checkpoint re-
ceptorthatisexpressedonactivatedTcells. Itsassociatedligands,
programmed death-ligands 1 and 2 (PD-L1 and PD-L2), are fre-
quently expressedonneoplastic cells. Ligand receptorbinding
results indownregulationof the immune response.Antibodies
targetingPD-1haveemergedaspromising therapies for several
typesofcancersbypromotingTcell–mediatedkilling.11Preclini-
cal models, including those for ovarian carcinoma, have dem-
onstrated a synergistic antitumor effect with niraparib and
anti–PD-1 drugs regardless of BRCA mutation status or PD-L1
expression.12The immunomodulatory functionofniraparibhas
beenproposedasapotentialmechanismfor this synergybased
on the observation that niraparib treatment significantly in-
creasedtheactivitiesof thestimulatorof interferongeneandin-
terferon pathways and enhanced intratumoral immune cell
infiltrationandupregulationofgranzymeB–positiveTcells.12,13
Othermechanisms, such as PARP inhibitor–mediated upregu-
lationofPD-L1expression,mayalsoplaya role in theactivityof
thiscombination.14,15TheTOPACIO/KEYNOTE-162(Niraparib in
Combination With Pembrolizumab in Patients With Triple-
NegativeBreastCancerorOvarianCancer) trialevaluatedthehy-
pothesis that niraparib combined with an anti–PD-1 antibody
(pembrolizumab)wouldbesafeandeffectiveinpopulationswith
difficult-to-treat ovarian carcinoma.
Methods
Study Design and Participants
Thismulticenter, open-label, single-armphases 1 and 2 study
evaluated the safety and efficacy of niraparib and pembroli-
zumabcombinationtherapy inpatientswithpreviously treated
advanced or metastatic triple-negative breast cancer (TNBC)
orovariancarcinoma (furtherdetails areavailable ineMethods
in Supplement 1). Data were collected from April 15, 2016,
through September 4, 2018. Patients were eligible regardless
of BRCA mutation status. Herein, we report the phase 1 por-
tion of the study (patients with TNBC or ovarian carcinoma)
and the results from the phase 2 ovarian carcinoma cohort.
Findings for the phase 2 cohort of patients with TNBCwill be
reported separately.
The phase 1 part of the study included a dose escalation
to determine the recommended phase 2 dose (RP2D) and
schedule of niraparib to be administered in combinationwith
the recommended dose of pembrolizumab. Patientswere en-
rolled at 34 sites in the United States. The study was con-
ducted in accordance with ethical principles founded in the
DeclarationofHelsinki.Thestudyprotocol (available inSupple-
ment 2) and/or other relevant documents received approval
by the institutional ethics committee, institutional review
board, and/or relevant competent authorities at each site. All
patients provided written informed consent to participate in
the study.
Procedures
Phase 1
We used a standard 6-plus-6 dose escalation design. Dosing
was initiated with a cohort treated at the starting dose of
Key Points
Question What is the clinical activity and safety of combination
therapy of niraparib plus pembrolizumab in patients with
platinum-based chemotherapy–resistant ovarian carcinoma or
those not eligible for retreatment with a platinum-based
chemotherapy?
Findings Sixty-two patients with ovarian carcinomawere enrolled
in this open-label, single-arm phases 1 and 2 study. Among the 60
evaluable patients, 3 had complete responses, 8 had partial
responses, and 28 had stable disease.
Meaning Combination niraparib plus pembrolizumab therapy
showed promising antitumor activity in patients with ovarian
carcinoma, warranting further investigation.
Research Original Investigation NiraparibWith Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
1142 JAMAOncology August 2019 Volume 5, Number 8 (Reprinted) jamaoncology.com
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Helsinki Univeristy Library User  on 10/25/2019
200 mg of oral niraparib once daily for days 1 to 21 and 200
mgof intravenouspembrolizumabonday1ofeach21-daycycle
(dose level 1). After a safety review, thenext-higher dose level
was opened for enrollment if less than one-third of patients
in dose level 1 experienced a dose-limiting toxic effect (DLT)
during cycle 1. Information on DLTs and related interven-
tions are detailed in the eMethods in Supplement 1.
Once dose level 1 was determined to be safe, a cohortwas
enrolled at dose level 2 and treatedwith a combinationof 300
mg of oral niraparib once daily and 200 mg of intravenous
pembrolizumab once every 21 days. No further dose escala-
tion for niraparibwas planned. Themaximum tolerated dose
wasdefinedas thehighestdosewithDLTsobserved in less than
one-third of patients during cycle 1 of combination treat-
ment. The RP2D was based on an evaluation of multiple end
points, including the DLT rate in first and subsequent cycles
of combination treatment, the rate of dose modifications for
non-DLT adverse events, the ability to manage toxic effects,
pharmacokinetics, niraparib dose intensity, and signs of
clinical efficacy.
Phase 2
All patients in phase 2 began treatment with the RP2D from
the phase 1 portion. Additional on-treatment assessments
were conducted in cycle 1 on days 8 and 15 and on day 1 of all
subsequent cycles. Safety assessments conducted through-
out the treatment period included physical examination,
measurement of vital signs, electrocardiography, Eastern
Cooperative Oncology Group performance status, and clini-
cal laboratory assessments (complete blood cell count, blood
chemical evaluation, thyrotropin level, thyroid function
tests, urinalysis, cancer antigen-125 level, and pregnancy
tests).
Radiographic evaluations to assess the extent of disease
wereconductedevery9weeksafterday1ofcycle 1duringstudy
treatment and/or at any timewhenprogressionof diseasewas
suspected. After 1 year of radiographic assessments, patients
had imaging performed every 12weeks until disease progres-
sion. If apatientdiscontinuedtreatment fora reasonother than
disease progression, death, withdrawal of consent, or loss to
follow-up, scans and cancer antigen-125 testing continued at
the specified intervals. Per the Response Evaluation Criteria
in Solid Tumors, version 1.1 (RECIST 1.1),16 patients who
achieveda complete responseor apartial responsehad the re-
sponse confirmedwith tumor imagingnoearlier than4weeks
after the first indication of response or at the next scheduled
scan (ie, 9 weeks later), whichever was clinically indicated.
Adverse eventswere evaluated according to theNational Can-
cer InstituteCommonTerminologyCriteria forAdverseEvents,
version 4.03. Biomarker testing is described in eMethods in
Supplement 1.
Outcomes
The primary objectives of phase 1 were to establish the RP2D
and dosing schedule of the niraparib and pembrolizumab
combination and to evaluate DLTs during the first cycle of
treatment. The primary objective of phase 2 was to estimate
the clinical activity of combination treatment with niraparib
and pembrolizumab in terms of objective response rate
(ORR; the best of complete or partial responses) assessed by
the investigators using RECIST 1.1. Secondary end points
included duration of response, disease control rate (best
response of complete or partial responses or stable disease),
and progression-free survival, all by RECIST 1.1, and overall
survival. Correlation of tumor BRCA (tBRCA) mutation status
and HRD status with other immune-related biomarkers and
with efficacy outcomes were exploratory end points.
Statistical Analysis
Data were analyzed from September 4, 2018, through Janu-
ary 30, 2019. Demographics, baseline characteristics, and
safety results were summarized descriptively. Response end
points were evaluated using the full analysis set, defined as
all patients in phase 1 and phase 2 with ovarian carcinoma
who received any amount of studymedication, as well as the
efficacy-evaluable analysis set, which included patients who
received any amount of study treatment and who had at
least 1 evaluable postbaseline tumor assessment. Target
enrollment of 48 patients was estimated to provide 82%
power to rule out the null hypothesis (≤15% ORR) when the
true ORR was 30% at the 1-sided 5% type I error rate. Assum-
ing that the true ORR was 35%, enrollment of 48 patients
was estimated to provide 94% power. Point estimates and
2-sided 90% CIs were provided for the analysis of ORR
and disease control rate. For time-to-event end points, the
median and corresponding 2-sided 95% CI were obtained
using Kaplan-Meier methods. Exploratory subgroup analy-
ses were performed by biomarker status (tBRCA, HRD, and
PD-L1), response to last platinum-based chemotherapy
(resistant, refractory, or not applicable), number of lines of
prior therapy, and prior bevacizumab use using the efficacy-
evaluable analysis set. Platinum-free interval (PFI) was
defined as the time between the end of the last platinum-
based chemotherapy to progression. Using the PFI, response
to the last platinum-based chemotherapy was classified as
follows: platinum refractory (PFI, ≤28 days), platinum resis-
tant (PFI, 29-179 days), and not applicable (due to toxic
effects or allergic reaction; PFI, ≥180 days).
All statistical analyses were performed using SAS soft-
ware, version 9.4 (SAS Institute Inc). A data cutoff date of
September 4, 2018, was used.
Results
From April 2016 through September 2017, 14 patients (9 with
ovarian carcinoma and 5 with TNBC) in phase 1 and 53
patients with ovarian carcinoma in phase 2 were enrolled
and received the initial dose of study treatment (median age,
60 years; range, 46-83 years). At the time of the data cutoff,
3 patients with ovarian carcinoma continued to receive
treatment. Fifty-nine patients with ovarian carcinoma dis-
continued treatment because of radiologic disease progres-
sion in 41, clinical disease progression in 8, an adverse event
in 5, patient request in 4, and a move out of the country in 1
(Figure 1).
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Basedon thesafetyprofiles andobservedDLTsatdose lev-
els 1 and 2 (eTable 1 in Supplement 1), the RP2D of oral ni-
raparib was determined to be 200mg once daily in combina-
tion with 200mg of intravenous pembrolizumab once every
21 days. The demographics and baseline characteristics were
similar in patients in phases 1 and 2 (eTable 2 in Supple-
ment 1); combined data are shown in Table 1.
Because of the similarity in the phases 1 and 2 ovarian
carcinoma populations, the data were pooled to perform
an integrated efficacy analysis. In the combined phases 1 and
2 ovarian carcinoma full-analysis population (n = 62),
3 patients had confirmed complete responses, 8 had con-
firmed partial responses, 28 had stable disease, 20 had pro-
gressive disease, and 3 were not evaluable. The confirmed
ORR of the combined population was 18% (90% CI, 10%-
28%). Of the 3 patients not evaluable in the full-analysis set,
2 discontinued before the first scan during treatment
was conducted (both owing to patient request), and an
additional patient (included in the efficacy-evaluable
population) had a postbaseline scan demonstrating stable
disease, but response was not evaluable because the dura-
tion requirement was not met. Four of the patients with
stable disease had a partial response that was not confirmed
by a subsequent scan. In the efficacy-evaluable population
(n = 60), the confirmed ORR of the combined population
was 18% (90% CI, 11%-29%), with a disease control rate of
65% (90% CI, 54%-75%) (Table 2 and Figure 2A-C).
Median duration of follow-up was 12.4 months (range,
1.2 to ≥23.0 months). In patients with ovarian carcinoma and
a confirmed complete or partial response, the median dura-
tion of response had not been reached at the time of the data
cutoff (range, 4.2 to ≥14.5 months) (eFigure in Supple-
ment 1). Eight patients with partial or complete responses
had a duration of response lasting longer than 6 months,
4 of whom achieved duration of longer than 9 months
(Figure 2B). In addition, 5 of these 8 patients with long-term
responses had platinum-refractory or platinum-resistant
disease and tBRCAwt tumors. Two of these patients were
continuing treatment at the time of data cutoff. Nine
patients with stable disease received treatment for longer
than 6 months; of these, 1 received treatment for at least
12.5 months (ongoing) and 1, for 13.2 months.
Exploratory analyses of biomarker subpopulations indi-
cate that the combination treatment of niraparib and pem-
brolizumab resulted in antitumor activity across the study
Figure 1. Enrollment, Treatment, and Outcomes
14 Patients enrolled in phase 1 and
received ≥1 dose of niraparib in
combination with pembrolizumab
9 With ovarian carcinoma
5 With triple-negative breast cancer
60 Included in integrated efficacy analysis
of efficacy-evaluable patients (≥1 scan
obtained during treatment)
62 Patients with ovarian carcinoma
enrolled in phases 1 and 2 and
received ≥1 dose of niraparib in
combination with pembrolizumab
9 From phase 1
53 From phase 2
Safety analysis and RP2D determined
2 Discontinued with
no postbaseline scan
RP2D indicates recommended phase 2 dose.
Table 1. Patient Characteristics at Baseline
Characteristic
Combined Phases 1 and 2 Patients
With Ovarian Carcinoma (n = 62)
Age, median (range), y 60 (46-83)
ECOG performance status, No. (%)a
0 44 (71)
1 18 (29)
Prior lines of therapy, median (range) 3 (1-5)
Prior bevacizumab, No. (%) 39 (63)
Prior chemotherapy, No. (%)b
Anthracycline 40 (65)
Cyclophosphamide 5 (8)
Gemcitabine hydrochloride 29 (47)
Paclitaxel 61 (98)
Platinum 62 (100)
Topotecan hydrochloride 3 (5)
Platinum status, No. (%)
Resistant 30 (48)
Refractory 17 (27)
Not applicablec 15 (24)
tBRCA status, No. (%)
BRCA1 mutation 9 (15)
BRCA2 mutation 2 (3)
BRCA wild type 49 (79)
Unknown 2 (3)
HRD status, No. (%)
HRD positive 22 (35)
HRD negative 33 (53)
HRD unknown 7 (11)
PD-L1 status, No. (%)d
Positive 35 (56)
Negative 21 (34)
Unknown 6 (10)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; HRD, homologous
recombination deficiency; PD-L1, programmed death-ligand 1; tBRCA, tumor
BRCA.
a Zero indicates fully active and able to perform all predisease activities without
restriction; 1, restricted in strenuous activity yet ambulatory and able to do
light work.
b Includes chemotherapy used in more than 1 patient; those used in only 1
patient are not listed.
c Includes patients with an interval free of platinum-based chemotherapy of at
least 180 days but unable to receive further platinum-based chemotherapy
(owing to toxic effect or allergic reaction).
d Positivity was based on a combined positive score of 1 provisional cutoff by
immunohistochemistry.
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population regardless of tBRCA mutation or HRD status
(Figure 2A). The ORRs for all biomarker-identified popula-
tions appeared to be similar (Table 3). A subgroup analysis of
additional baseline characteristics, including tumor PD-L1
status, did not reveal any specific marker that drove clinical
activity from the combination treatment regimen. Although
we noted that patients with fewer lines of therapy had
higher response rates than those with 3 or more prior lines,
the CIs overlapped. Response rates were similar regardless of
platinum status or prior bevacizumab treatment. In this
study, 39 patients (63%) had previously received treatment
with bevacizumab. Similar ORRs were observed in patients
who had received bevacizumab compared with those who
did not (19% [90% CI, 9%-33%] vs 17% [90% CI, 6%-36%]).
In all treated patients, the median progression-free sur-
vivalwas 3.4months (95%CI, 2.1-5.1months),with 6- and 12-
monthprogression-free survival estimated tobe31%and 12%,
respectively (Figure2C).Theoverall survivaldatawerenotma-
ture at the time of this analysis.
The most common treatment-related adverse events of
any grade (n = 53) in phase 2 were fatigue (28 [53%]), nausea
(22 [42%]), anemia (19 [36%]), and constipation (19 [36%])
(eTable 3 in Supplement 1). The most common treatment-
related adverse events of at least grade 3 were anemia
(11 [21%]) and thrombocytopenia (5 [9%]). In addition, the
most common adverse effects of laboratory investigations
of at least grade 3 were decreased platelet count (3 [6%]),
decreased white blood cell count (3 [6%]), and decreased
neutrophil count (2 [4%]). No treatment-related patient
deaths or cases of myelodysplastic syndrome or acute
myeloid leukemia occurred. Immune-related adverse events
were defined as the adverse events of clinical interest
that have been commonly associated with pembrolizu-
mab.17 Immune-related adverse effects deemed associated
with treatment by the investigator occurred in 10 patients
(19%); immune-related adverse effects of grade 3 or greater
occurred in 3 patients (6%) (eTable 3 in Supplement 1).
Immune-related adverse effects of any grade regardless of
causality occurred in 14 patients (26%) and of at least grade 3
in 4 (8%). The only grade 3 immune-related adverse effect
regardless of causality that occurred in 2 or more patients
was hyperglycemia in 2 patients (4%): 1 with a history of dia-
betes and 1 with hyperglycemia at screening that worsened
during treatment. No grade 4 immune-related adverse
effects occurred.
Discussion
This study has shown that the combination treatment of ni-
raparib and an anti–PD-1 antibody appears to be well toler-
atedandpotentiallyprovides clinical activityby tumor shrink-
ageanddisease stabilization inpatientswith recurrentovarian
carcinoma.Nonewtoxicitysignalswereobserved,andtheregi-
mencould represent apotential newtherapeutic option in this
patient population.
The study patient population was clinically diverse;
most had tumors that were tBRCAwt, had been previously
treated with bevacizumab, and had acquired platinum-
resistant or platinum-refractory disease. Response rates and
stable disease rates were similar across the biomarker-
defined populations as defined by tBRCAmutation and HRD
status. Single-agent PARP inhibitors have demonstrated an
ORR of approximately 25% to 30%18,19 in patients with
platinum-resistant ovarian carcinoma and a BRCAmutation,
but limited activity has been observed in patients with BRCA
mutationsandplatinum-refractorydisease (0%-14%).20,21 The
efficacy of PARP inhibitor monotherapy is even lower for pa-
tientswho lack aBRCAmutation andhaveplatinum-resistant
(ORR,approximately 5%)22,23orplatinum-refractory (ORR,0%)
ovarian carcinoma.24 Similarly, single-agent PD-1/PD-L1
inhibitorshaveanORRof4%to10%inplatinum-resistantovar-
ian carcinoma irrespective of PD-L1 expression levels.11,25,26
The combination of anti-PD-1 antibody andniraparib appears
to improve efficacy in the tBRCAwt (ORR, 19%) and non-HRD
(ORR, 19%) patient populations when compared with mono-
therapy with either agent. Given the modest activity of
PD-1/PD-L1 inhibitors in ovarian carcinoma, trials of combi-
nations of PD-1/PD-L1 antibodies with antiangiogenic agents,
chemotherapy, and targeted agents are being developed
and/or have been reported. As an example, the combination
of nivolumab and bevacizumab was associated with an
ORR of 11% in platinum-resistant ovarian carcinoma,27 and
the combination of avelumab and doxorubicin was associ-
ated with an ORR of 13.3%.28 Although previous trials23,29
have shown that platinum status and response rates to
PARP inhibitors are correlated, patients in our study with
reduced sensitivities to platinum also showed clinical activ-
ity. Notably, 5 of the 8 patients who had a duration of re-
sponse lasting more than 6 months had platinum-refractory
or platinum-resistant ovarian carcinoma and tBRCAwt
tumors.
Benefit from immunotherapy canmanifest itself via pro-
longed periods of stable disease in patients. In this study,
9patientswithstabledisease received treatment formore than
6months, 2ofwhomreceived treatment for longer than 1year.
This finding suggests that this combination therapymaybeof
Table 2. Integrated Efficacy Analysis of ORR for Phases 1 and 2
Best Overall Response Response Data (n = 60)
Complete response, No. (%) 3 (5)
Partial response, No. (%) 8 (13)
Stable disease, No. (%)a 28 (47)
Progressive disease, No. (%) 20 (33)
Inconclusive, No. (%)b 1 (2)
ORR, % (90% CI)c 18 (11-29)
DCR, % (90% CI)d 65 (54-75)
Abbreviations: DCR, disease control rate; ORR, objective response rate.
a Four patients had an unconfirmed partial response.
bOne patient had an evaluable postbaseline scan but was not evaluable
for response; the postbaseline scan demonstrated stable disease and was
therefore included in the efficacy-evaluable analysis set. However, minimum
duration requirement of stable disease was not met.
c Includes patients with complete and partial responses.
d Includes patients with complete and partial responses and stable disease.
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therapeutic value even in patients who do not achieve a
RECIST 1.1 response.
Most patients in this study had previously received treat-
ment with bevacizumab. Importantly, this treatment did not
affect outcomes; responses were similar in patients who had
received bevacizumab comparedwith thosewhodid not. Be-
cause the combination of chemotherapy and bevacizumab is
the standard of care for patientswith recurrent ovarian carci-
noma,mostof thesepatientswill receive this treatmentat some
point in their disease; therefore, it is important that the effi-
cacy of therapies given in later lines is not detrimentally af-
fected by prior bevacizumab treatment. The current stan-
dard of care for patients with platinum-resistant ovarian
carcinoma treated with prior bevacizumab is non–platinum-
based chemotherapy, which has response rates of less
than 10%.
The incidence of thrombocytopenia of any grade or of
grade 3 or higherwas substantially lower in this study than in
other niraparib trials.10 This finding is likely due to the lower
200-mg dose of niraparib once daily that was selected as the
RP2D when administered in combination with pembroli-
zumab. Compared with the 300-mg dose of niraparib, the
200-mgdosehasbeen foundto reduce the incidenceof throm-
bocytopenia inpatientswith recurrent ovarian carcinomaand
a baseline bodyweight of less than 77 kg andbaseline platelet
count of less than 150 × 103/μL.30 No additional safety con-
Figure 2. Antitumor Activity of Niraparib in CombinationWith Pembrolizumab
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Responses were confirmed using Response Evaluation Criteria in Solid Tumors,
version 1.1. HRD indicates homologous recombination deficiency;
PD-L1, programmed death-ligand 1; tBRCAmut, tumor BRCAmutated;
and tBRCAwt, tumor BRCAwild type.
a All patients with tBRCAmut also had HRD-positive disease.
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cerns due to immune-related adverse events were noted.
The values for immune-related adverse events regardless of
causality (any grade, 26%; grade ≥3, 8%) are comparable to
those from a study of pembrolizumab monotherapy for
PD-L1–positive non–small cell lung cancer (any grade, 29.2%;
grade ≥3, 9.7%; treatment-related, immune-related adverse
events were not reported). No new safety signals were ob-
servedwith the combination treatment of niraparib andpem-
brolizumab compared with the safety profiles of either drug
as monotherapy.
Limitations
This studywas a signal-seeking phase 2 trial with 62 patients
with ovarian carcinoma enrolled; therefore, the results
presented herein will need to be validated in a larger trial.
Although thepredefined statistical criteria for this studywere
not met (null ≤15%), the observed ORR is of interest, espe-
cially in the tBRCAwt and non-HRD patient populations; du-
rable responseswere observed across platinumstatus, tBRCA
mutations, and tissue HRD status (although patient numbers
in the various subgroups are relatively small).
Conclusions
Niraparib in combinationwith a PD-1 inhibitor showedprom-
isingactivity forpatientswithplatinum-resistantandplatinum-
refractory recurrent ovarian carcinoma, particularly in pa-
tients with tBRCAwt or non-HRD disease, regardless of prior
bevacizumab treatment. No new safety signals were identi-
fied; hematologic adverse events were minimized with a
200-mgstartingdoseofniraparib in thephase2portionof this
study.
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